The Reed-Sternberg cell: Molecular characterization by proteomic analysis with therapeutic implications

Annals of Clinical and Laboratory Science

Volumn 32, Issue 4, 2002, Pages 339-351

  Brown, Robert E ^a   Kamal, Nazmi R ^a  

^a GEISINGER MEDICAL CENTER   (United States)

Author keywords

Hodgkin's disease; Immunohistochemistry; Molecular signaling pathways; Proteomics; Reed Sternberg cell

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR; CATHEPSIN D; CD20 ANTIGEN; CD30 ANTIGEN; DIPEPTIDYL CARBOXYPEPTIDASE; IMATINIB; KI 67 ANTIGEN; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; RETINOID; STEM CELL FACTOR; STRESS ACTIVATED PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1; ACTIVIN RECEPTOR 1; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN DERIVATIVE; PROTEOME; TGF BETA TYPE I RECEPTOR; TGF-BETA TYPE I RECEPTOR; TGFB1 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; BRIGHT FIELD MICROSCOPY; GROWTH INHIBITION; HODGKIN DISEASE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; PRIORITY JOURNAL; PROTEOMICS; RECEPTOR UPREGULATION; REED STERNBERG CELL; SIGNAL TRANSDUCTION; CELL DIVISION; METABOLISM; PATHOLOGY; PHYSIOLOGY;

PHRAGMITES;

ACTIVIN RECEPTORS, TYPE I; ANGIOTENSINS; CELL DIVISION; HODGKIN DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; PEPTIDYL-DIPEPTIDASE A; PROTEOME; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RECEPTORS, ANGIOTENSIN; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; REED-STERNBERG CELLS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 0036729950     PISSN: 00917370     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (81)

1. Reed DM. On the pathologic changes in Hodgkin's disease, with special reference to its relation to tuberculosis. Johns Hopkins Hosp Rep 1902;10: 133-196.
2. Brown RE. Histogenesis of Reed-Sternberg and dendritic interdigitating cells in nodular sclerosing Hodgkin's disease. Immunohistochemical evidence for monocytoid precursors. Ann Clin Lab Sci 1997; 27:329-337.
3. Oudejans JJ, Kummer JA, Jiwa M, van DerValk P, Ossenkoppele GJ, Kluin PM, Kluin-Nelemans JC, Meijer CJ. Granzyme B expression in Reed-Sternberg cells of Hodgkin's disease. Am J Path 1996;148: 233-240.
4. Taylor CR, Riley CR. Molecular morphology of Hodgkin lymphoma. Appl Immunohistochem Mol Morphol 2001;9:187-202.
5. Cossman J, Annunziata CM, Barash S, Staudt L, Dillon P, He WW, Ricciardi-Castagnoli P, Rosen CA, Carter KC. Reed-Sternberg cell genome expression supports a B-cell lineage. Blood 1999;94:411-416.
6. Müschen M, Rajewsky K, Braüninger A, Baur AS, Oudejans JJ, Roers A, Hansmann ML, Küppers R. Rare occurrence of classical Hodgkin's disease as a T-cell lymphoma. J Exp Med 2000;191:387-394.
7. Pinto A, Gloghini A, Gattei V, Aldinucci D, Zagonel V, Carbone A. Expression of the c-kit receptor in human lymphomas is restricted to Hodgkin's disease and CD30+ anaplastic large cell lymphomas. Blood 1994;83:785-792.
8. Lokker NA, O'Hare JP, Barsoumian A, Tomlinson JE, Ramakrishnan V, Fretto LJ, Giese NA. Functional importance of platelet-derived growth factor (PDGF) receptor extracellular immunoglobulin-like domains. Identification of PDGF binding site and neutralizing monoclonal antibodies. J Biol Chem 1997;272:33037-33044.
9. Oertel J, Oertel B, Schleicher J, Huhn D. Immunophenotyping of blasts in human bone marrow. Ann Hematol 1996;72:125-129.
10. Yoshida H, Takakura N, Hirashima M, Kataoka H, Tsuchida K, Nishikawa S. Hematopoietic tissues, as a playground of receptor tyrosine kinases of the PDGF-receptor family. Develop Comp Immunol 1998;22:321-332.
11. Krettek A, Ostergren-Lungen G, Fager G, Rosmond C, Bondjers G, Lustig F. Expression of PDGF receptors and ligand-induced migration of partially differentiated human monocyte-derived macrophages. Influence of INF-gamma and TGF-beta. Atherosclerosis 2001;156:267-275.
12. Tsukamoto T, Matsui T, Nakata H, Ito M, Natazuka T, Fukase M, Fujita T. Interleukin-1 enhances the response of osteoblasts to platelet-derived growth factor through the alpha receptor-specific upregulation. J Biol Chem 1991;266:10143-10147.
13. Wang YZ, Zhang P, Rice AB, Bonner JC. Regulation of interleukin-1 beta-induced platelet-derived growth factor receptor-alpha expression in rat pulmonary myofibroblasts by p38 mitogen-activated protein kinase. J Biol Chem 2000;275:22550-22557.
14. Gerdes J, Kretschmer C, Zahn G, Ernst M, Jones DB, Flad HD. Immunoenzymatic assessment of interferon-gamma in Hodgkin and Sternberg-Reed cells. Cytokine 1990;2:307-310.
15. Merz H, Fliedner A, Orscheschek K, Binder T, Sebald W, Muller-Hermelink HK, Feller AC. Cytokine expression in T-cell lymphomas and Hodgkin's disease. Its possible implication in autocrine or paracrine production as a potential basis for neoplastic growth. Am J Pathol 1991;139:1173-1180.
16. Serrano D, Ghiotto F, Roncella S, Airoldi I, Cutrona G, Truini M, Burgio VL, Baroni CD, Ferrarini M, Pistoia V. The patterns of IL2, IFN-gamma, IL4 and IL5 gene expression in Hodgkin's disease and reactive lymph nodes are similar. Haematologica 1997;82:542-549.
17. Benharroch D, Prinsloo I, Apte RN, Yermiahu T, Geffen DB, Yanai-Inbar I, Gopas J. Interleukin-1 and tumor necrosis factor-alpha in the Reed-Sternberg cells of Hodgkin's disease. Correlation with clinical and morphological "inflammatory" features. Eur Cytokine Netw 1996;7:51-57.
18. Gelderloos JA, Rosenkranz S, Bazenet C, Kazlauskas A. A role for Src in signal relay by the platelet-derived growth factor alpha receptor. J Biol Chem 1998;273: 5908-5915.
19. Hooshmand-Rad R, Yokote K, Heldin CH, Claesson-Welsh L. PDGF alpha-receptor mediated cellular responses are not dependent on Src family kinases in endothelial cells. J Cell Sci 1998;111:607- 614.
20. Rosenkranz S, DeMali KA, Gelderloos JA, Bazenet C, Kazlauskas A. Identification of the receptor-associated signaling enzymes that are required for platelet-derived growth factor-AA-dependent chemotaxis and DNA synthesis. J Biol Chem 1999; 274:28335-28343.
21. Vignais ML, Sadowski HB, Watling D, Rogers NC, Gilman M. Platelet-derived growth factor induces phosphorylation of multiple JAK family kinases and STAT proteins. Mol Cell Biol 1996;16:1759-1769.
22. Vignais ML, Gilman M. Distinct mechanisms of activation of Stat1 and Stat3 by platelet-derived growth factor receptor in a cell-free system. Mol Cell Biol 1999;19:3727-3735.
23. Hagood JS, Miller PJ, Lasky JA, Tousson A, Guo B, Fuller GM, McIntosh JC. Differential expression of platelet-derived growth factor-alpha receptor by Thy-1(-) and Thy-1(+) lung fibroblasts. Am J Physiol 1999;277:L218-224.
24. 2-terminal kinase-1 and antagonizes PDGF receptor-beta-induced phenotypic transformation. J Biol Chem 2000;275:19076-19082.
25. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, Lydon NB. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Therap 2000;295:139-145.
26. Bowman T, Broome MA, Sinibaldi D, Wharton W, Pledger WJ, Sedivy JM, Irby R, Yeatman T, Courtneidge SA, Jove R. Stat 3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. PNAS 2001;98:7319-7324.
27. Kube D, Holtick U, Vocherodt M, Ahmadi T, Haier B, Behrmann I, Heinrich PC, Diehl V, Tesch H. STAT3 is constitutively activated in Hodgkin cell lines. Blood 2001;98:762-770.
28. Benharrock D, Yermiahut T, Geffen DB. Expression of c-myc and c-ras oncogenes in the neoplastic and non-neoplastic cells of Hodgkin disease. Eur J Haematol 1995;55:178-183.
29. Jiwa NM, Kanavaros P, van der Valk P, Walboomers JM, Horstman A, Vos W, Mullink H, Meijer CJ. Expression of c-myc and bcl-2 oncogene products in Reed-Sternberg cells independent of presence of Epstein-Barr virus. J Clin Pathol 1993;46:211-217.
30. Sakalidou A, Kanavaros P, Tzardi M, Kalmanti M. The expression of myc and ras oncogene protein in childhood lymphomas. Anticancer Res 1996;16: 487-491.
31. Sabattini E, Gerdes J, Gherlinzoni F, Poggi S, Zucchini L, Melilli G, Grigioni F, DelVecchio MT, Leoncini L, Falini B. Comparison between the monoclonal antibodies Ki-67 and PC10 in 125 malignant lymphomas. J Pathol 1993;169:397-403.
32. Abele MC, Valente G, Kerim S, Navone R, Onesti P, Chiusa L, Resegotti L, Palestro G. Significance of cell proliferation index in assessing histological prognostic categories in Hodgkin's disease. An immunohistochemical study with Ki67 and MIB-1 monoclonal antibodies. Haematologica 1997;82: 281-285.
33. Ohshima K, Haraoka S, Fujiki T, Yoshioka S, Suzumiva J, Kanda M, Kikuchi M. Expressions of cyclin E, A, and B1 in Hodgkin and Reed-Sternberg cells: Not suppressed by cyclin-dependent kinase inhibitor p21 expression. Pathol Int 1999;49:506-512.
34. Kanavaros P, Stefanaki K, Vlachonikolis J, Eliopoulos G, Kakolyris S, Rontogianni D, Gorgoulis V, Georgoulias V. Expression of p53, p21/waf1, bcl-2, bax, Rb and Ki67 proteins in Hodgkin's lymphomas. Histol Histopathol 2000;15:445-453.
35. Gruss HJ, Brach MA, Drexler HG, Bross KJ, Herrmann F. Interleukin 9 is expressed by primary and cultured Hodgkin and Reed-Sternberg cells. Cancer Res 1992;52:1026-1031.
36. Zhu YX, Sun HB, Tsang ML, McMahel J, Grigsby S, Yin T, Yang YC. Critical cytoplasmic domains of human interleukin-9 receptor alpha chain in interleukin-9-mediated cell proliferation and signal transduction. J Biol Chem 1997;272:21334-21340.
37. Crocker J, Smith PJ. A quantitative study of mast cells in Hodgkin's disease. J Clin Pathol 1984;37: 519-522.
38. Sharma VK, Agrawal A, Pratap VK, Nagar AM, Mehrota ML. Mast cell reactivity in lymphoma: A preliminary communication. Ind J Cancer 1992; 29:61-65.
39. Molin D, Fischer M, Xiang Z, Larsson U, Harvima I, Venge P, Nilsson K, Sundstrom C, Enbald G, Nilsson G. Mast cells express functional CD30 ligand and are the predominant CD30L-positive cells in Hodgkin's disease. Br J Haematol 2001;114: 616-623.
40. Abe J, Deguchi J, Matsumoto T, Takuwa N, Noda M, Ohno M, Makuuchi M, Kurokawa K, Takuwa Y. Stimulated activation of platelet-derived growth factor receptor in vivo in balloon-injured arteries: A link between angiotensin II and intimal thickening. Circulation 1997;96:1906-1913.
41. Saito Y, Berk BC. Transactivation: A novel signaling pathway from angiotensin II to tyrosine kinase receptors. J Mol Cell Cardiol 2001;33:3-7.
42. Paxton WG, Marrero MB, Klein JD, Delafontaine P, Berk BC, Bernstein KE. The angiotensin II AT1 receptor is tyrosine and serine phosphorylated and can serve as a substrate for the src family of tyrosine kinases. Biochem Biophys Res Commun 1994;200: 260-267.
43. Schieffer B, Luchtefeld M, Braun S, Hilfiker A, Hilfiker-Kleiner D, Drexler H. Role of NAD(P)H oxidase in angiotensin II-induced JAK/STAT signaling and cytokine induction. Circulat Res 2000; 87:1195-1201.
44. Mondorf UF, Geiger H, Herrero M, Zeuzem S, Piiper A. Involvement of the platelet-derived growth factor receptor in angiotensin II-induced activation of extracellular regulated kinases 1 and 2 in human mesangial cells. FEBS Lett 2000;472:129-132.
45. Deguchi J, Makuuchi M, Nakaoka T, Collins T, Takuwa Y. Angiotensin II stimulates platelet-derived growth factor-B chain expression in newborn rat vascular smooth muscle cells and neointimal cells through Ras, extracellular signal-regulated protein kinase, and c-Jun N-terminal protein kinase mechanisms. Circul Res 1999;85:565-574.
46. 2-terminal kinase activation in cardiac hypertrophy in hypertensive rats. Hypertension 2000;36:511-516.
47. 2terminal kinase is mediated by Rac1 and Nck. J Biol Chem 2001;276:22003-22010.
48. Naftilan AJ, Pratt RE, Dzau VJ. Induction of platelet-derived growth factor A-chain and c-myc gene expressions by angiotensin II in cultured rat vascular smooth muscle cells. J Clin Invest 1989; 83:1419-1424.
49. Su JZ, Chen DG, Wu KG, Chen SC, Hu WY, Wang XY, Rui HB, Wang HJ, Xu CS. Inhibitory effects of captopril on c-myc expression during left ventricular hypertrophy. Acta Pharmacol Sinica 1998;19:535-540.
50. Viard I, Hall SH, Jaillard C, Berthelon MC, Saez JM. Regulation of c-fos, c-jun and jun-B messenger ribonucleic acids by angiotensin-II and corticotropin in ovine and bovine adrenocortical cells. Endocrinology 1992;130:1193-2000.
51. Kreuzer J, Watson L, Herdegen T, Loebe M, Wende P, Kubler K. Effects of HMG-CoA reductase inhibition on PDGF-and angiotensin II-mediated signal transduction: Suppression of C-Jun and C-Fos in human smooth muscle cells in vitro. Eur J Med Res 1999;4:135-143.
52. Knecht H, Berger C, McQuain C, Rothenberger S, Bachmann E, Martin J, Esslinger C, Drexler HG, Cai YC, Quesenberry PJ, Odermatt BE Latent membrane protein 1 associated signaling pathways are important in tumor cells of Epstein-Barr virus negative Hodgkin's disease. Oncogene 1999;18: 7161-7167.
53. Hsu SM, Xie SS, el-Okda MO, Hsu PL. Correlation of c-fos/c-jun expression with histiocytic differentiation in Hodgkin's Reed-Sternberg cells. Examination in HDLM-1 subclones with spontaneous differentiation. Am J Pathol 1992;140:155-165.
54. Karlsson C, Lindell K, Ottosson M, Sjostrom L, Carlsson B, Carlsson LM. Human adipose tissue expresses angiotensinogen and enzymes required for its conversion to angiotensin II. J Clin Endocrinol Metab 1998;83:3925-3929.
55. Karwa LC, Sun Y, Campbell SE, Tyagi SC, Dhalla AK, Kandala JC, Weber KT. Pouch tissue and angiotensin peptide generation. J Mol Cell Cardiol 1998;30:1401-1413.
56. Newcom SR, Kadin ME, Ansari AA, Diehl V. L-428 nodular sclerosing Hodgkin's cell secretes a unique transforming growth factor-beta active at physiologic pH. J Clin Invest 1988;82:1915-1921.
57. Newcom SR, Tagra KK, Kadin ME. Neutralizing antibodies against transforming growth factor beta potentiate the proliferation of Ki-1 positive lymphoma cells. Further evidence for negative autocrine regulation by transforming growth factor beta. Am J Pathol 1992;140:709-718.
58. Newcom SR, Tagra KK. High molecular weight transforming growth factor beta is excreted in the urine in active nodular sclerosing Hodgkin's disease. Cancer Res 1992;52:6768-6773.
59. Hsu SM, Lin J, Xie SS, Hsu PL, Rich S. Abundant expression of transforming growth factor-beta 1 and -beta 2 by Hodgkin's Reed-Sternberg cells and by reactive T lymphocytes in Hodgkin's disease. Human Pathol 1993;24:249-255.
60. Newcom SR, Gu L. Transforming growth factor beta 1 messenger RNA in Reed-Sternberg cells in nodular sclerosing Hodgkin's disease. J Clin Pathol 1995;48:160-163.
61. Gibbons GH, Pratt RE, Dzau VJ. Vascular smooth muscle cell hypertrophy vs. hyperplasia. Autocrine transforming growth factor-beta 1 expression determines growth response to angiotensin II. J Clin Invest 1992;90:456-461.
62. McCaffrey TA, Du B, Fu C, Bray PJ, Sanborn TA, Deutsch E, Tarazona N, Shaknovitch A, Newman G, Patterson C, Bush HL Jr. The expression of TGF-beta receptors in human atherosclerosis: Evidence for acquired resistance to apoptosis due to receptor imbalance. J Mol Cell Cardiol 1999;31:1627-1642.
63. Inman GJ, Allday MJ. Resistance to TGF-beta 1 correlates with a reduction of TGF-beta type II receptor expression in Burkitt's lymphoma and Epstein-Barr virus transformed B lymphoblastoid cell lines. J Gen Virol 2000;81:1567-1578.
64. Newcom SR, Kadin ME, Ansari AA. Production of transforming growth factor-beta activitiy by Ki-1 positive lymphoma cells and analysis of its role in the regulation of Ki-1 positive lymphoma growth. Am J Pathol 1988;131:569-577.
65. Cheng AL, Chuang SE, Su IJ. Factors associated with the therapeutic efficacy of retinoic acids on malignant lymphomas. J Formos Med Ass 1997;96: 525-534.
66. Ruiz-Gines JA, Perez-Caballero C, O'Valle F, Rodriguez-Puyol M, Rodriguez-Puyol D. Captopril inhibits pp60 (c-src) tyrosine phosphorylation in cultured human mesangial cells. Eur J Pharmacol 1997;336:251-256.
67. Inwang ER, Puddefoot JR, Brown CL, Goode AW, Marsigliante S, Ho MM, Payne JG, Vinson GP. Angiotensin II type 1 receptor expression in human breast tissues. Br J Cancer 1997;75:1279-1283.
68. Yoshizawa M, Miyazaki H, Kojima S. Retinoids potentiate transforming growth factor-beta activity in bovine endothelial cells through up-regulating the expression of transforming growth factor-beta receptors. J Cell Physiol 1998;176:565-573.
69. Turley JM, Falk LA, Ruscetti FW, Kasper JJ, Francomano T, Fu T, Bang OS, Birchenall-Roberts MC. Transforming growth factor beta 1 functions in monocytic differentiation of hematopoietic cells through autocrine and paracrine mechanisms. Cell Growth Diff 1996;7:1535-1544.
70. Taipale J, Matikainen S, Hurme M, Keski-Oja J. Induction of transforming growth factor beta 1 and its receptor expression during myeloid leukemia cell differentiation. Cell Growth Diff 1994;5:1309-1319.
71. Cohen PS, Letterio JJ, Gaetano C, Chan J, Matsumoto K, Sporn MB, Thiele CJ. Induction of transforming growth factor beta 1 and its receptors during all-trans-retinoic acid (RA) treatment of RA responsive human neuroblastoma cell lines. Cancer Res 1995;55:2380-2386.
72. Lee HY, Walsh GL, Dawson MI, Hong WK, Kurie JM. All-trans-retinoic acid inhibits Jun N-terminal kinase-dependent signaling pathways. J Biol Chem 1998;273:7066-7071.
73. Lee HY, Sueoka N, Hong WK, Mangelsdorf DJ, Claret FX, Kurie JM. All-trans-retinoic acid inhibits Jun-N terminal kinase by increasing dual-specificity phosphatase activity. Mol Cell Biol 1999;19:1973-1980.
74. Fisher GJ, Talwar HS, Lin J, Lin P, McPhillips F, Wang Z, Li X, Wan Y, Kang S, Voorhees JJ. Retinoic acid inhibits induction of c-Jun protein by ultraviolet radiation that occurs subsequent to activation of mitogen-activated protein kinase pathways in human skin in vivo. J Clin Invest 1998;101:1432-1440.
75. Moreno-Manzano V, Ishikawa Y, Lucio-Cazana J, Kitamura M. Suppression of apoptosis by all-transretinoic acid. Dual intervention in the c-Jun N-terminal kinase-AP-1 pathway. J Biol Chem 1999; 16:20251-20258.
76. Ozeki A, Tsukamoto I. Retinoic acid repressed the expression of c-fos and c-jun and induced apoptosis in regenerating rat liver after partial hepatectomy. Biochim Biophys Acta 1999;450:308-319.
77. Gianni M, Kalac Y, Ponzanelli I, Rambaldi A, Terao M, Garattini E. Tyrosine kinase inhibitor STI571 potentiates the pharmacologic activity of retinoic acid in acute promyelocytic leukemia cells: Effects on degradation of RARalpha and PML-RARalpha. Blood 2001;97:3234-3243.
78. Hsu SM, Hsu PL. Lack of effect of colony-stimulating factors, interleukins, interferons, and tumor necrosis factor on the growth and differentiation of cultured Reed-Sternberg cells. Comparison with effects of phorbol ester and retinoic acid. Am J Pathol 1990;136:181-189.
79. Hsu SM, Xie SS, Hsu PL. Cultured Reed-Sternberg cells HDLM-1 and KM-H2 can be induced to become histiocytelike cells. H-RS cells are not derived from lymphocytes. Am J Pathol 1990;137: 353-367.
80. Lindner V, Reidy MA. Platelet-derived growth factor ligand and receptor expression by large vessel endothelium in vivo. Am J Pathol 1995;146:1488-1497.
81. Nakajima Y, Sato K, Morita H, Torikai S, Hidano A, Nishioka K, Kashiwazaki S. Severe progressive erosive arthritis in multicentric reticulohistiocytosis: Possible involvement of cytokines in synovial proliferation. J Rheumatol 1992;19:1643-1646.